KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Enterprise Value (2016 - 2025)

Emergent BioSolutions' Enterprise Value history spans 16 years, with the latest figure at -$209.1 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 98.01% year-over-year to -$209.1 million; the TTM value through Dec 2025 reached -$209.1 million, down 98.01%, while the annual FY2025 figure was -$209.1 million, 98.01% down from the prior year.
  • Enterprise Value reached -$209.1 million in Q4 2025 per EBS's latest filing, up from -$249.2 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$71.0 million in Q2 2024 to a low of -$642.6 million in Q4 2022.
  • Average Enterprise Value over 5 years is -$283.3 million, with a median of -$245.1 million recorded in 2022.
  • Peak YoY movement for Enterprise Value: soared 82.62% in 2023, then plummeted 281.69% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$576.3 million in 2021, then decreased by 11.5% to -$642.6 million in 2022, then skyrocketed by 82.62% to -$111.7 million in 2023, then rose by 5.46% to -$105.6 million in 2024, then plummeted by 98.01% to -$209.1 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Enterprise Value are -$209.1 million (Q4 2025), -$249.2 million (Q3 2025), and -$271.0 million (Q2 2025).